PeproMene Bio to Present Groundbreaking CAR T Therapy Data at ASH 2025 PeproMene Bio will showcase its innovative CAR T therapy PMB-CT01 for B-cell malignancies at the upcoming ASH 2025 conference, highlighting its promising results.

PeproMene Bio to Present Groundbreaking CAR T Therapy Data at ASH 2025 #USA #Irvine #PeproMene_Bio #PMB-CT01 #ASH_2025

PeproMene Bio's PMB-CT01 Selected for Presentations at ASH 2025 Annual Meeting PeproMene Bio announces that two abstracts on PMB-CT01 have been accepted for oral presentations at ASH 2025, showcasing its promising results in treating B-cell malignancies.

PeproMene Bio's PMB-CT01 Selected for Presentations at ASH 2025 Annual Meeting #USA #Irvine #PeproMene_Bio #PMB-CT01 #BAFFR-CAR_T

Recent Data from PeproMene Bio's Clinical Trial Selected for Two Presentations at ASH 2025 PeproMene Bio's PMB-CT01 study data has been accepted for two significant presentations at the upcoming ASH 2025 Annual Meeting, highlighting promising results.

Recent Data from PeproMene Bio's Clinical Trial Selected for Two Presentations at ASH 2025 #USA #Irvine #PeproMene_Bio #PMB-CT01 #ASH_2025

PeproMene Bio Announces Exciting Data Presentations for PMB-CT01 at 2025 ASH Annual Meeting PeproMene Bio's PMB-CT01 BAFFR-CAR T therapy shows promising results for B-cell malignancies, poised for two oral presentations at ASH 2025.

PeproMene Bio Announces Exciting Data Presentations for PMB-CT01 at 2025 ASH Annual Meeting #USA #Irvine #PeproMene_Bio #PMB-CT01 #BAFFR-CAR_T

PeproMene Bio's PMB-CT01 Selected for Key Presentations at ASH 2025 PeproMene Bio reveals promising results for PMB-CT01 in treating relapsed B-cell malignancies at the upcoming ASH 2025 Annual Meeting, highlighting safety and efficacy.

PeproMene Bio's PMB-CT01 Selected for Key Presentations at ASH 2025 #USA #Irvine #B-ALL #PeproMene_Bio #B-NHL

PeproMene Bio Announces Full Remission in First Patient with Follicular Lymphoma Treated with CAR-T Therapy PeproMene Bio has reported that the first patient with follicular lymphoma treated with BAFF-R CAR-T therapy achieved full remission, showcasing promising results in cancer treatment.

PeproMene Bio Announces Full Remission in First Patient with Follicular Lymphoma Treated with CAR-T Therapy #USA #Irvine #CAR-T_therapy #Follicular_Lymphoma #PeproMene_Bio

Promising Breakthrough in Treating Indolent Follicular Lymphoma with CAR-T Therapy The first patient treated with BAFF-R directed CAR-T cells by PeproMene Bio achieves complete remission. A significant advancement in lymphoma treatment.

Promising Breakthrough in Treating Indolent Follicular Lymphoma with CAR-T Therapy #USA #California #CAR-T_therapy #Follicular_Lymphoma #PeproMene_Bio

First Patient with Follicular Lymphoma Achieves Complete Response with BAFF-R Targeting CAR-T Cells PeproMene Bio announces that the first patient with follicular lymphoma treated with BAFF-R CAR-T cells has achieved complete remission, marking a significant advancement in cancer therapy.

First Patient with Follicular Lymphoma Achieves Complete Response with BAFF-R Targeting CAR-T Cells #USA #Irvine #Follicular_Lymphoma #PeproMene_Bio #BAFF-R_CAR-T

Breakthrough in Follicular Lymphoma Treatment with BAFF-R Targeting CAR-T Cells PeproMene Bio announces a significant milestone in cancer treatment as the first patient with follicular lymphoma achieves complete remission using BAFF-R targeting CAR-T cells.

Breakthrough in Follicular Lymphoma Treatment with BAFF-R Targeting CAR-T Cells #USA #Irvine #Follicular_Lymphoma #PeproMene_Bio #BAFF-R_CAR-T

Revolutionary CAR-T Cell Therapy Shows Promising Results in Follicular Lymphoma Treatment PeproMene Bio announces a groundbreaking achievement in treating follicular lymphoma with CAR-T cells, marking hope for patients with this challenging disease.

Revolutionary CAR-T Cell Therapy Shows Promising Results in Follicular Lymphoma Treatment #USA #Irvine #Follicular_Lymphoma #PeproMene_Bio #BAFF-R_CAR-T

PeproMene Bio and IFLI Announce $11 Million Investment for Innovative Lymphoma Treatment PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation have announced an $11 million investment to advance the PMB-CT01 treatment for relapsed or refractory follicular lymphoma.

PeproMene Bio and IFLI Announce $11 Million Investment for Innovative Lymphoma Treatment #USA #Irvine,_California #PeproMene_Bio #IFLI #PMB-CT01

PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement PeproMene Bio, Inc. has secured an $11 million investment to advance PMB-CT01, a CAR T cell therapy targeted at relapsed/refractory follicular lymphoma, following encouraging initial results.

PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement #USA #Irvine #PeproMene_Bio #IFLI #PMB-CT01

PeproMene Bio and IFLI Invest $11 Million for Promising Lymphoma Therapy in Patients PeproMene Bio announces an $11 million investment to enhance the development of PMB-CT01, a CAR T-cell therapy for lymphoma patients, following promising trial results.

PeproMene Bio and IFLI Invest $11 Million for Promising Lymphoma Therapy in Patients #United_States #Irvine #PeproMene_Bio #IFLI #PMB-CT01

PeproMene Bio Secures $11M for Innovative CAR T Cell Therapy in Cancer Treatment PeproMene Bio, in collaboration with IFLI, secures an $11 million investment to advance a groundbreaking CAR T cell therapy for follicular lymphoma in clinical trials.

PeproMene Bio Secures $11M for Innovative CAR T Cell Therapy in Cancer Treatment #USA #CAR_T_Therapy #Follicular_Lymphoma #Irvine,_California #PeproMene_Bio

PeproMene Bio Secures $11M Investment to Enhance CAR T Cell Therapy for Lymphoma Patients In a significant boost for cancer therapy, PeproMene Bio has gained an $11 million investment to enhance its promising CAR T cell therapy for treating follicular lymphoma.

PeproMene Bio Secures $11M Investment to Enhance CAR T Cell Therapy for Lymphoma Patients #USA #Irvine #CAR_T_Therapy #Follicular_Lymphoma #PeproMene_Bio